- Hematopoietic Stem Cell
- Skeletal Muscle Stem Cell
- Mesenchymal Stem Cells
- Lymphocytes
- Others
Personalized Cell Therapies Market size was valued at USD 12,252.24 million in 2022 and is poised to grow at a CAGR of 23.6% from 2023-29. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers engaged in the manufacturing and supply of personalized cell therapies. Research & Development is evolving, various cell types developed into treatments as novel cell therapies due to its potential applications. Bone marrow transplant or hematopoietic stem cell transplant widely used cell therapy due to the treatment of blood cancer. Increased prevalence of cancer, a rise in research and adoption of advanced technologies are expected attract the demand for the market.
Personalized Cell Therapies Market Key Development:
- On August 19, 2016, the European Commission has granted conditional marketing authorization for Zalmoxis, patient-specific adjunctive treatment in haploidentical hematopoietic stem cell transplantation for adults with hematological malignancies.
Global Personalized Cell Therapies Market Summary
Study Period
2023-29
Base Year
2022
CAGR
23.6%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Personalized Cell Therapies Market Dynamics
The rise in prevalence of chronic disorders and unmet needs in current treatment methods are expected to catapult the personalized cell therapies market. Increasing prevalence of various disorders such as diabetes, cancer, autoimmune disorders, neurovascular disorders is expected to create demand for personalized cell therapies market over the forecast period. Moreover, potential applications of cell therapies include treating autoimmune disease, cancers, infectious disease, urinary problems, spinal cord injuries, rebuilding damaged cartilage in joints, improving a weakened immune system, neurological disorders are expected to create lucrative opportunities for the market.
North-America Got Significant Share of
Personalized Cell Therapies Market Regional Analysis
U.S. market is expected to grow at the significant rate due to state-of-art healthcare infrastructure, increase in R&D, public and private funds for cellular therapies are expected to propel the market. Asia Pacific market is expanding at lucrative growth rate owing to increase in healthcare expenditure, raising awareness about novel cellular therapies in China and India. Rise in the medical tourism due to cost effectiveness is expected to trigger the demand for market over the forecast period. Stringent regulations, limited awareness in low-income countries are major restraints of the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The personalized cell therapies market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Personalized Cell Therapies Market Segmentation
By Cell Type
By Application
- Cardiovascular Disorders
- Diabetes
- Neurological Disorders
- Cancer
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
Frequently Asked Questions
The personalized cell therapies market size was valued at USD 12,252.24 million in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
PCT Cell Therapy Services, LLC (U.S) S. Stem Cell, Inc. (U.S) Bellicum Pharmaceuticals, Inc. (U.S) Saneron CCEL Therapeutics, Inc. (U.S) StemGenex (U.S)
| 1.Executive Summary |
| 2.Global Personalized Cell Therapies Market Introduction |
| 2.1.Global Personalized Cell Therapies Market - Taxonomy |
| 2.2.Global Personalized Cell Therapies Market - Definitions |
| 2.2.1.Cell Type |
| 2.2.2.Application |
| 2.2.3.Region |
| 3.Global Personalized Cell Therapies Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Personalized Cell Therapies Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Personalized Cell Therapies Market By Cell Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Hematopoietic Stem Cell |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Skeletal Muscle Stem Cell |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Mesenchymal Stem Cells |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Lymphocytes |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Personalized Cell Therapies Market By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Cardiovascular Disorders |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Diabetes |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Neurological Disorders |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cancer |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Personalized Cell Therapies Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Personalized Cell Therapies Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Cell Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Hematopoietic Stem Cell |
| 8.1.2.Skeletal Muscle Stem Cell |
| 8.1.3.Mesenchymal Stem Cells |
| 8.1.4.Lymphocytes |
| 8.1.5.Others |
| 8.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Cardiovascular Disorders |
| 8.2.2.Diabetes |
| 8.2.3.Neurological Disorders |
| 8.2.4.Cancer |
| 8.2.5.Others |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Personalized Cell Therapies Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Hematopoietic Stem Cell |
| 9.1.2.Skeletal Muscle Stem Cell |
| 9.1.3.Mesenchymal Stem Cells |
| 9.1.4.Lymphocytes |
| 9.1.5.Others |
| 9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Cardiovascular Disorders |
| 9.2.2.Diabetes |
| 9.2.3.Neurological Disorders |
| 9.2.4.Cancer |
| 9.2.5.Others |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 9.3.7. |
| 10.Asia Pacific (APAC) Personalized Cell Therapies Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hematopoietic Stem Cell |
| 10.1.2.Skeletal Muscle Stem Cell |
| 10.1.3.Mesenchymal Stem Cells |
| 10.1.4.Lymphocytes |
| 10.1.5.Others |
| 10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Cardiovascular Disorders |
| 10.2.2.Diabetes |
| 10.2.3.Neurological Disorders |
| 10.2.4.Cancer |
| 10.2.5.Others |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Personalized Cell Therapies Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hematopoietic Stem Cell |
| 11.1.2.Skeletal Muscle Stem Cell |
| 11.1.3.Mesenchymal Stem Cells |
| 11.1.4.Lymphocytes |
| 11.1.5.Others |
| 11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Cardiovascular Disorders |
| 11.2.2.Diabetes |
| 11.2.3.Neurological Disorders |
| 11.2.4.Cancer |
| 11.2.5.Others |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Personalized Cell Therapies Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Cell Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hematopoietic Stem Cell |
| 12.1.2.Skeletal Muscle Stem Cell |
| 12.1.3.Mesenchymal Stem Cells |
| 12.1.4.Lymphocytes |
| 12.1.5.Others |
| 12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Cardiovascular Disorders |
| 12.2.2.Diabetes |
| 12.2.3.Neurological Disorders |
| 12.2.4.Cancer |
| 12.2.5.Others |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.PCT Cell Therapy Services, LLC (U.S) |
| 13.2.2.S. Stem Cell, Inc. (U.S) |
| 13.2.3.Bellicum Pharmaceuticals, Inc. (U.S) |
| 13.2.4.Saneron CCEL Therapeutics, Inc. (U.S) |
| 13.2.5.StemGenex (U.S) |
| 13.2.6.Vericel Corporation.(U.S) |
| 13.2.7.Cytori Therapeutics Inc.(U.S.) |
| 13.2.8.MolMed S.p.A. (Italy) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- PCT Cell Therapy Services, LLC (U.S)
- S. Stem Cell, Inc. (U.S)
- Bellicum Pharmaceuticals, Inc. (U.S)
- Saneron CCEL Therapeutics, Inc. (U.S)
- StemGenex (U.S)
- Vericel Corporation.(U.S)
- Cytori Therapeutics Inc.(U.S.)
- MolMed S.p.A. (Italy)